| Filed On | Filing |
|---|---|
| 13 May 2026 |
Form 3: Hughes Owen, Director
No securities owned |
| 13 May 2026 |
Form 3: Murphy Christopher M., Chief Financial Officer
No securities owned |
| 03 Apr 2026 |
Form 3: Gray Susannah, Director
No securities owned |
| 01 Apr 2026 |
Form 3: ANAPTYSBIO, Inc, 10% owner · First Tracks Biotherapeutics, Inc.
Holds 100 shares of Common Stock |
| 18 Sep 2023 |
Form 3: Orwin John A, Director
No securities owned |
| 06 Apr 2023 |
Form 3: Jain Rita, Director
No securities owned |
| 30 Nov 2021 |
Form 3: Faga Daniel, Director
No securities owned |
| 12 Apr 2021 |
Form 3: Nodelman Oleg, Director
Holds 7,151,624 shares of Common Stock |
| 19 Jan 2021 |
Form 3: Marquet Magda, Director
No securities owned |
| 14 Jan 2021 |
Form 3: EcoR1 Capital, Llc, 10% owner
Holds 3,813,324 shares of Common Stock |
| 31 Jul 2020 |
Form 3: Lizzul Paul F., Chief Medical Officer
No securities owned |
| 15 Jul 2020 |
Form 3: Mulroy Dennis, Chief Financial Officer
No securities owned |
| 26 Sep 2019 |
Form 3: Hamill Laura, Director
Holds 0 shares of No securities beneficially owned |
| 08 Aug 2018 |
Form 3: Loumeau Eric J, General Counsel
Holds 0 shares of No securities are beneficially owned |
| 06 Mar 2018 |
Form 3: Fenton Dennis M, Director
No securities owned |
| 24 Aug 2017 |
Form 3: Ware J. Anthony, Director
No securities owned |
| 25 Jan 2017 |
Form 3: Avalon Ventures Vii L P, 10% owner and 2 others
Holds 2,036,932 shares of Common Stock |
| 25 Jan 2017 | Form 3: Novo A/S, 10% owner |
| 25 Jan 2017 | Form 3: Topper James N, Director |
| 25 Jan 2017 | Form 3: Schoeneck James A, Director |
Loading...